Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
•
Renal Cell Carcinoma
In what situations do you escalate the dose of Axitinib over 5 mg bid when administered with Pembrolizumab for clear cell RCC?
Related Questions
How are you utilizing subcutaneous Nivolumab in genitourinary cancers?
What are your top takeaways from ASCO GU 2025?
How do you manage recurrent asymptomatic transaminitis from VEGF TKI in a patient renal cell carcinoma who needs drug to control disease?
What would you offer for a very young patient with metastatic renal medullary carcinoma who has progressed on cisplatin-based chemotherapy?
When considering cytoreductive nephrectomy in metastatic kidney cancer, in which situations would you consider nephron-sparing approaches such as partial nephrectomy or SBRT?
What therapy would you use for a patient with metastatic TFE3 rearranged RCC who progressed on initial pembrolizumab/lenvatinib?
In a patient with de novo metastatic RCC s/p Ipi/Nivo with partial response and residual viable RCC on cytoreductive nephrectomy, would you add cabozantinib or other TKI prior to disease progression?
Which patients are you utilizing subcutaneous PD-1/L1 inhibitors instead of the intravenous formulation?
Are you dose reducing/omitting IV dexamethasone as a pre-medication for anti-emesis in patients with MIBC when using durvalumab/gemcitabine/cisplatin?
In light of evidence supporting enfortumab vedotin with pembrolizumab (EVP) in muscle-invasive urothelial cancer, would one consider perioperative EVP for node-negative high-risk UTUC?
